Accessibility Menu
 
Arrow-Thin-Down
S&P 500
6,591.90
+0.5%
+35.53
Arrow-Thin-Down
DJI
46,429.49
+0.7%
+305.43
Arrow-Thin-Down
NASDAQ
21,929.83
+0.8%
+167.93
Arrow-Thin-Down
Bitcoin
$69,417.00
-2.4%
-$1,701.44
Arrow-Thin-Down
AMZN
$211.71
+2.2%
+$4.47
Arrow-Thin-Down
GOOG
$289.59
+0.1%
+$0.39
Arrow-Thin-Down
META
$594.67
+0.3%
+$1.75
Arrow-Thin-Down
MSFT
$370.86
-0.5%
-$1.88
Arrow-Thin-Down
NVDA
$178.62
+1.9%
+$3.42
Arrow-Thin-Down
TSLA
$385.95
+0.8%
+$2.92
Most Active StocksDaily Stock GainersDaily Stock Losers

Why Celgene Stock Was Down 3% Today

What's not to love about Celgene earnings?

By Michael Douglass and Dave Williamson – Jul 24, 2014 at 7:05PM EST

Celgene (CELG +0.00%) turned in a quarter that beat analyst expectations on the top and bottom lines, with revenue up 17% year-over-year and adjusted EPS up 18% year-over-year, yet the market didn't appear too impressed (the stock sold off about 3% today).

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson dive into the key takeaways from earnings.

Read Next

About the Author

Michael Douglass
Former Deputy Managing Editor, Fool.com. I started in Healthcare, but you'll find me writing regularly about biotech, dividend stocks, and personal finance.
TMFEnterprise

Stocks Mentioned

Celgene Stock Quote
Celgene
NASDAQ: CELG
--
--

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services